New Data Showing that Transgene and NEC's Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023

New Phase I data confirm promising immunogenicity and efficacy profile of TG4050, an individualized neoantigen cancer vaccine developed by Transgene in collaboration with NEC Corporation In the head

Related Keywords

France ,United States ,Paris ,France General ,Florida ,United Kingdom ,Ankara ,Turkey ,Institut Curie ,Alexandra Martinez ,Lucie Larguier ,Ben Brahim ,Sylvie Berrebi ,Meetingin Orlando ,Yujie Zhao ,Transgene Euronext ,Christian Ottensmeier ,Le Tourneau ,Christophe Le Tourneau ,Masamitsu Kitase ,Jean Pierre Delord ,Healthcare Life Sciences Business ,Nec Ai Drug Development Business ,American Association For Cancer Research ,Head Of The Department Drug Development ,Head Of Surgical Department ,Ai Drug Development Division ,Jolla Institute For Immunology ,University Of Liverpool ,Astrazeneca ,Twitter ,Corporate Communications ,Clatterbridge Cancer Centre ,Euronext Paris ,American Association ,Cancer Research ,Annual Meetingin Orlando ,Corporate Senior ,Managing Director ,Serious Adverse Events ,Consultant Medical Oncologist ,Drug Development ,Consultant Medical Oncology ,Consultant Immunology ,Associate Professor ,Mayo Clinic ,Associate Head ,Surgical Department ,Vaccinia Ankara ,Artificial Intelligence ,Prediction System ,Development Business ,Risk Factors ,Universal Registration Document ,Data ,Showing ,Transgene ,Individualized ,Dancer ,Vaccine ,G4050 ,Induces ,Strong ,Specific ,Immune ,Responses ,Against ,Rumors ,Resented ,Racr ,023 ,